Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
COVID-19 vaccine vial and syringe on a CDC-vaccination record card on blue background.
Moderna announced the vaccine’s per-dose price hike in early 2023, which received heavy criticism from the public and senators.
iStock, Wirestock

Moderna CEO Justifies Price Hike, Denies NIH as Vaccine Co-Creators

“The price is not linked to the company’s performance, the price is linked to the value of the product,” says Stéphane Bancel, Moderna CEO

Photo portrait of swathi kodaikal
Swathi Kodaikal, MSc
Photo portrait of swathi kodaikal

Swathi Kodaikal, MSc, holds a master’s degree in biotechnology and has worked in places where actual science and research happen. Blending her love for writing with science, Swathi enjoys demystifying complex research findings for readers from all walks of life. On the days she doesn’t write, she learns and performs Kathak, sings, makes plans to travel, and obsesses over cleanliness.

ViewFull Profile
Learn about ourEditorial Policies.
Published:Apr 06, 2023
|2 min read
Register for free to listen to this article
Listen with Speechify

Sen. Bernie Sanders (I-VT), Democratic lawmakers, and some Republicans urged Moderna's CEO, Stéphane Bancel, to steer away from quadrupling the price of Spikevax® COVID-19 vaccine in the latest hearing of the Senate Health, Education, Labor, and Pensions (HELP) Committee. Bancel announced the vaccine’s price hike—to about $110–$130 per dose—in early 2023, which received heavy public backlash. 

Several senators raised questions about the affordability of the vaccine and whether patients will truly be able to access Moderna’s proposed patient assistance program. In February 2023, the company said in a statement, “Everyone in the United States will have access to Moderna's COVID-19 vaccine regardless of their ability to pay.” But Moderna did not release any details about the assistance program yet.

“While Moderna may wish to rewrite history, it is widely acknowledged that both Moderna and the NIH created this vaccine together,” said Sanders in a press release. This came to light in December, when Moderna finally agreed to pay about $400 million to the NIH, per a new royalty-bearing license agreement, after collaborating with the scientists from the National Institute of Allergy and Infectious Diseases (NIAID) for years.

In his defense, Bancel said the price hike is justified because, in the postpandemic market, the company will have to expand its warehouse space, take financial responsibility for wasted doses, and account for supply chain complexities. Bancel also emphasized that the price hike wasn’t motivated by a desire to boost the company’s flagging revenue, as insinuated by Sanders in his earlier statements.

Sen. Bill Cassidy (R-LA) said, “We should not hate the thought of a person or company making a profit [so much] that we lose sight of the ideas and accomplishments their profit is rewarding.”

Bancel claimed that the cost savings from people being hospitalized from COVID-19 outweigh even higher prices for vaccines: “We want to learn from what is not working from current programs.”